Bloomington, Indiana – In a strategic move to meet the rising demand for injectable medications, Simtra BioPharma Solutions has announced the acquisition of a 65-acre site in Bloomington, Indiana. The new property, located at 301 N. Curry Pike, was purchased from Cook Group and includes over 300,000 square feet of space, providing significant room for future expansion.
Simtra, a global contract development and manufacturing organization (CDMO), is known for its focus on injectable therapies and advanced cancer treatments. This acquisition marks a major step in expanding its U.S.-based operations and manufacturing capacity, complementing its well-established capabilities in Halle/Westfalen, Germany.
“This purchase gives us the foundation to grow with purpose, building the advanced injectable capacity our customers need while strengthening our presence in North America,” said Franco Negron, Chief Executive Officer, Simtra BioPharma Solutions. “It reflects our long-term commitment to delivering vital injectable products and helping our customers navigate complex global supply chains.”
The newly acquired site will allow Simtra to explore the addition of advanced production lines, including its first U.S.-based commercial-scale manufacturing capabilities for oncology-related injectable drugs. Plans under consideration include state-of-the-art isolator-based filling lines for vials and prefilled syringes. These lines would be tailored to customer-specific needs using Simtra’s flexible “build-to-suit” approach.
This latest investment is part of a broader expansion strategy for Simtra, which has been making major financial commitments on both sides of the Atlantic. In the U.S., the company is already investing $250 million in ongoing construction at its existing Bloomington site. Meanwhile, in Germany, Simtra recently completed a new production facility valued at over $100 million, as well as a $14 million conjugation and purification suite for antibody-drug conjugates (ADCs), a rapidly evolving class of targeted cancer therapies.
The combined U.S. and European expansions reflect a deliberate, balanced global growth strategy. By strengthening its presence in North America while continuing to build on its European capabilities, Simtra aims to offer flexible and responsive manufacturing services to its global pharmaceutical partners.
The company is now working closely with local officials in Monroe County to develop a phased plan for the new site. While specific development timelines have not yet been announced, Simtra has indicated that more details will be shared in the coming weeks as project planning moves forward.
This move comes as pharmaceutical companies around the world face increasing pressure to secure dependable manufacturing partners amid global supply chain disruptions and growing demand for complex biologic and oncology treatments.
With this acquisition, Simtra is positioning itself not only as a key player in injectable drug production but also as a company willing to invest heavily in infrastructure that supports innovation, supply chain stability, and long-term partnerships with its clients.
